A. Marcantonio

发表

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.

Tsung-Teh Wu, J. Murray, M. Mäki, 2017, Gastroenterology.

Evaluation of antihypertensive effects of once‐a‐day isradipine and fosinopril: A double‐blind crossover study by means of ambulatory blood pressure monitoring

F. Perticone, P. Mattioli, R. Maio, 1995, Clinical cardiology.

A Randomized, Placebo-Controlled, Dose-Escalation, Phase 1 Study of the Safety and Pharmacokinetics of Amphotericin B Inhalation Powder in Healthy Subjects.

M. Eldon, N. Mufti, A. Kugler, 2007 .

AR101 Oral Immunotherapy for Peanut Allergy

William H. Yang, N. Rupp, G. Toit, 2018, The New England journal of medicine.

Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.

K. Kaukinen, M. Mäki, K. Laurila, 2014, Gastroenterology.

Efficacy and Safety of AR101 in Peanut Allergy: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)

T. Casale, A. Burks, B. Vickery, 2018 .

Celiac Disease Symptom Frequency and Severity Using A Disease‐Specific Patient‐Reported Outcome Diary: Observations From A Psychometric Validation Study in 202 Patients: 1509

S. Acaster, D. Leffler, B. Lebwohl, 2012 .

Abstract P6-12-15: Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

R. Nanda, T. Pluard, J. O’Shaughnessy, 2017 .

Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.

K. Kaukinen, M. Mäki, K. Laurila, 2014, Gastroenterology.